A MULTI-CENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 2 STUDY OF THE EFFICACY, SAFETY AND TOLERABILITY OF RG1662 IN ADULTS AND ADOLESCENTS WITH DOWN SYNDROME (CLEMATIS)
Phase of Trial: Phase II
Latest Information Update: 27 Oct 2017
Price : $35 *
At a glance
- Drugs Basmisanil (Primary)
- Indications Down syndrome
- Focus Therapeutic Use
- Acronyms CLEMATIS
- Sponsors Roche
- 01 Jul 2016 Status changed from recruiting to completed.
- 27 Jun 2016 This trial was completed in Spain (end date: 06-05-2016), according to European Clinical Trials Database.
- 04 Apr 2016 Status changed from active, no longer recruiting to recruiting as reported by Clinicaltrials.gov.